Artem Sokolov

Artem Sokolov

Auto-generated profile, based on publicly available information

Artem Sokolov

Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SRSteve Rodriguez
Steve Rodriguez
CHClemens Hug
Clemens Hug
PTPetar Todorov
Petar Todorov
NMNienke Moret
Nienke Moret
SBSarah A. Boswell
Sarah A. Boswell
ASArtem Sokolov
Artem Sokolov
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. We present DRIAD (Drug Repurposing In AD), a machine learning framework that quantifies potential associations between the pathology of AD severity (the Braak stage) and molecular mechanisms as encoded in lists of gene names. DRIAD is applied to lists of genes arising from perturbations in differentiated human neural cell cultures by 80 FDA-approved and clinically tested drugs, producing a ranked list of possible repurposing candidates. Top-scoring drugs are inspected for common trends among their targets. We propose that the DRIAD method can be used to nominate drugs that, after additional validation and identification of relevant pharmacodynamic biomarker(s), could be readily evaluated in a clinical trial.

25 November 2021 in Nature Methods
Verified
Journal Article
Open access
PDF file
DSDenis Schapiro
Denis Schapiro
ASArtem Sokolov
Artem Sokolov
CYClarence Yapp
Clarence Yapp
YCYu-An Chen
Yu-An Chen
JMJeremy L Muhlich
Jeremy L Muhlich
PSPeter K. Sorger
Peter K. Sorger
Highly multiplexed tissue imaging makes detailed molecular analysis of single cells possible in a preserved spatial context. However, reproducible analysis of large multichannel images poses a substantial computational challenge. Here, we describe a modular and open-source computational pipeline, MCMICRO, for performing the sequential steps needed to transform whole-slide images into single-cell data. We demonstrate the use of MCMICRO on tissue and tumor images acquired using multiple imaging platforms, thereby providing a solid foundation for the continued development of tissue imaging software.

11 March 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
DSDenis Schapiro
Denis Schapiro
CYClarence Yapp
Clarence Yapp
ASArtem Sokolov
Artem Sokolov
SRSheila M. Reynolds
Sheila M. Reynolds
YCYu-An Chen
Yu-An Chen
PSPeter K. Sorger
Peter K. Sorger

9 February 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
TSThais S Sabedot
Thais S Sabedot
TMTathiane M Malta
Tathiane M Malta
JSJames Snyder
James Snyder
KNKevin Nelson
Kevin Nelson
MWMichael Wells
Michael Wells
HNHoutan Noushmehr
Houtan Noushmehr
Background: The detection of somatic mutations in cell-free DNA (cfDNA) from liquid biopsy has emerged as a noninvasive tool to monitor the follow-up of cancer patients. However, the significance of cfDNA clinical utility remains uncertain in patients with brain tumors, primarily because of the limited sensitivity cfDNA has to detect real tumor-specific somatic mutations. This unresolved challenge has prevented accurate follow-up of glioma patients with noninvasive approaches.Methods: Genome-wide DNA methylation profiling of tumor tissue and serum cfDNA of glioma patients.Results: Here, we developed a noninvasive approach to profile the DNA methylation status in the serum of patients with gliomas and identified a cfDNA-derived methylation signature that is associated with the presence of gliomas and related immune features. By testing the signature in an independent discovery and validation cohorts, we developed and verified a score metric (the “glioma-epigenetic liquid biopsy score” or GeLB) that optimally distinguished patients with or without glioma (sensitivity: 100%, specificity: 97.78%). Furthermore, we found that changes in GeLB score reflected clinicopathological changes during surveillance (eg, progression, pseudoprogression, and response to standard or experimental treatment).Conclusions: Our results suggest that the GeLB score can be used as a complementary approach to diagnose and follow up patients with glioma.

10 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMarie-Laure Charpignon
Marie-Laure Charpignon
BVBella Vakulenko-Lagun
Bella Vakulenko-Lagun
BZBang Zheng
Bang Zheng
CMColin Magdamo
Colin Magdamo
BSBowen Su
Bowen Su
MAMark W. Albers
Mark W. Albers
Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset. Mixed results are emerging from prior observational studies. To address this complexity, we deploy a causal inference approach accounting for the competing risk of death in emulated clinical trials using two distinct electronic health record systems. In intention-to-treat analyses, metformin use associates with lower hazard of all-cause mortality and lower cause-specific hazard of dementia onset, after accounting for prolonged survival, relative to sulfonylureas. In parallel systems pharmacology studies, the expression of two AD-related proteins, APOE and SPP1, was suppressed by pharmacologic concentrations of metformin in differentiated human neural cells, relative to a sulfonylurea. Together, our findings suggest that metformin might reduce the risk of dementia in diabetes patients through mechanisms beyond glycemic control, and that SPP1 is a candidate biomarker for metformin’s action in the brain.

1 January 2021
Verified
Conference Paper
Open access
PDF file
ASAndrea Schioppa
Andrea Schioppa
DVDavid Vilar
David Vilar
ASArtem Sokolov
Artem Sokolov
KFKatja Filippova
Katja Filippova
Andrea Schioppa, David Vilar, Artem Sokolov, Katja Filippova. Proceedings of the 2021 Conference on Empirical Methods in Natural Language Processing. 2021.